Advancing Therapeutic Delivery using Precision Shells

Granza Bio is pioneering advancements in therapeutic delivery through its innovative "precision shell" technology, which is inspired by the body's immune system. This platform is designed to synthetically recreate "attack particles," which are autonomous entities derived from cytotoxic immune cells. These attack particles, discovered by co-founder Prof. Dustin at the University of Oxford, have the potential to significantly enhance the treatment of various diseases, including cancers, autoimmunity, and infections. The precision shell technology allows for the effective packaging and targeted delivery of therapeutic agents, ensuring that they reach specific tissues and hard-to-access organs.

The precision shell platform is versatile, capable of delivering a wide range of cargo types, including attack particles, RNAs, proteins, and genetic modifiers. One of its key advantages is its ability to overcome immunological activation that can be triggered by traditional delivery vehicles, thereby improving the efficacy of the therapeutic agents. By focusing on precise delivery mechanisms, Granza Bio aims to revolutionize how therapeutic cargo is administered, ultimately leading to more effective treatments and better patient outcomes.

United States

Granza Bio is a biotechnology company developing a novel delivery “shell” platform to direct therapeutic cargo to specific tissues. For their lead candidate, Granza Bio is leveraging the discovery of the immune system’s powerful suite of weapons, “attack particles”. Utilizing their advanced delivery platform, they aim to target these "attack particles" against a range of diseases such as cancer, autoimmune disorders, and infections. Interested to know more? 


Granza Bio

Company Details